The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171)

A critique of the submission from Celgene. Addendum

Nicola Huxley , Linda Long, Simon Briscoe, Martin Hoyle

Research output: Book/ReportCommissioned report

Original languageEnglish
PublisherUniversity of Exeter
Commissioning bodyThe National Institute for Health and Care Excellence (NICE)
Number of pages54
Publication statusPublished - 2016
Externally publishedYes

Cite this